| abstract |
The inventors of the present invention have succeeded in improving stability under acidic conditions, heterogeneity derived from disulfide in the hinge region, heterogeneity derived from the H chain C terminal, and stability in high concentration preparations in the normal region of the antibody Respectively. In addition, it succeeded in finding a novel normal region sequence that reduced binding to Fc receptors while minimizing the emergence of new T-cell epitope peptides. This resulted in the discovery of a normal antibody region that improved physical properties (stability and uniformity), immunogenicity, safety, and pharmacokinetics. |